Table 2.
Vaccination status of presumed omicron BA.2 cases and controls stratified by SARS-CoV-2 primary infection (pre-omicron or omicron BA.1)
|
All infections analysis |
Symptomatic infections analysis* |
||||
|---|---|---|---|---|---|
| Cases (n=37 732) | Controls (n=73 507) | Cases (n=23 371) | Controls (n=30 542) | ||
| Pre-omicron primary infection | |||||
| Overall | 2521 (6·7%) | 7360 (10·0%) | 1495 (6·4%) | 2643 (8·7%) | |
| Non-vaccinated | 109 (0·3%) | 265 (0·4%) | 57 (0·2%) | 41 (0·1%) | |
| One vaccine dose | 342 (0·9%) | 729 (1·0%) | 214 (0·9%) | 285 (0·9%) | |
| Primary infection, first dose | 340 (0·9%) | 722 (1·0%) | 212 (0·9%) | 283 (0·9%) | |
| First dose, primary infection | 2 (<0·1%) | 7 (<0·1%) | 2 (<0·1%) | 2 (<0·1%) | |
| Two vaccine doses | 897 (2·4%) | 2665 (3·6%) | 540 (2·3%) | 987 (3·2%) | |
| Primary infection, two doses | 815 (2·2%) | 2376 (3·2%) | 486 (2·1%) | 860 (2·8%) | |
| First dose, primary infection, second dose | 39 (0·1%) | 107 (0·1%) | 24 (0·1%) | 56 (0·2%) | |
| Two doses, primary infection | 43 (0·1%) | 182 (0·2%) | 30 (0·1%) | 71 (0·2%) | |
| Three vaccine doses | 1173 (3·1%) | 3701 (5·0%) | 684 (2·9%) | 1330 (4·4%) | |
| Primary infection, three doses | 1028 (2·7%) | 3177 (4·3%) | 594 (2·5%) | 1118 (3·7%) | |
| First dose, primary infection, second and third doses | 83 (0·2%) | 271 (0·4%) | 52 (0·2%) | 99 (0·3%) | |
| Two doses, primary infection, third dose | 62 (0·2%) | 253 (0·3%) | 38 (0·2%) | 113 (0·4%) | |
| Omicron BA.1 primary infection | |||||
| Overall | 659 (1·7%) | 12315 (16·8%) | 330 (1·4%) | 5600 (18·3%) | |
| Non-vaccinated | 125 (0·3%) | 727 (1·0%) | 43 (0·2%) | 119 (0·4%) | |
| One vaccine dose | 9 (<0·1%) | 109 (0·1%) | 3 (<0·1%) | 33 (<0·1%) | |
| Primary infection, first dose | 1 (<0·1%) | 6 (<0·1%) | 1 (<0·1%) | 2 (<0·1%) | |
| First dose, primary infection | 8 (<0·1%) | 103 (<0·1%) | 2 (<0·1%) | 31 (<0·1%) | |
| Two vaccine doses | 262 (0·7%) | 5322 (7·2%) | 147 (0·6%) | 2519 (8·2%) | |
| Two doses, primary infection | 262 (0·7%) | 5314 (7·2%) | 147 (0·6%) | 2517 (8·2%) | |
| First dose, primary infection, second dose | 0 | 8 (<0·1%) | 0 | 2 (<0·1%) | |
| Three vaccine doses | 263 (0·7%) | 6157 (8·4%) | 137 (0·6%) | 2929 (9·6%) | |
| Three doses, primary infection | 243 (0·6%) | 5679 (7·7%) | 124 (0·5%) | 2716 (8·9%) | |
| Two doses, primary infection, third dose | 20 (0·1%) | 478 (0·7%) | 13 (0·1%) | 213 (0·7%) | |
| No previous SARS-CoV-2 infection | |||||
| Overall | 34 552 (91·6%) | 53 832 (73·2%) | 21 546 (92·2%) | 22 299 (73·0%) | |
| Non-vaccinated | 672 (1·8%) | 1043 (1·4%) | 343 (1·5%) | 125 (0·4%) | |
| One vaccine dose | 136 (0·4%) | 193 (0·3%) | 68 (0·3%) | 45 (0·1%) | |
| Two vaccine doses | 6717 (17·8%) | 8939 (12·2%) | 4387 (18·8%) | 3839 (12·6%) | |
| Three vaccine doses | 27 027 (71·6%) | 43 657 (59·4%) | 16 748 (71·7%) | 18 290 (59·9%) | |
*
Including only participants who had symptoms at the time of specimen collection according to the indication for testing.